Advisors Asset Management Inc. Sells 196 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Advisors Asset Management Inc. lowered its position in United Therapeutics Co. (NASDAQ:UTHR) by 3.9% in the 3rd quarter, Holdings Channel reports. The firm owned 4,787 shares of the biotechnology company’s stock after selling 196 shares during the quarter. Advisors Asset Management Inc.’s holdings in United Therapeutics were worth $1,715,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in United Therapeutics in the 2nd quarter valued at $30,000. Innealta Capital LLC purchased a new stake in United Therapeutics in the second quarter worth $33,000. USA Financial Formulas bought a new stake in shares of United Therapeutics during the third quarter worth $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of United Therapeutics during the third quarter valued at $82,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $372.89 on Monday. The company has a market capitalization of $16.65 billion, a PE ratio of 16.38, a P/E/G ratio of 1.08 and a beta of 0.56. The company has a 50-day simple moving average of $365.06 and a two-hundred day simple moving average of $332.32. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.38 EPS. On average, equities analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares in the company, valued at approximately $947,597.55. The trade was a 74.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 224 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. The trade was a 3.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,227 shares of company stock worth $43,671,320. Insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company lifted their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Finally, The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.